CREATE Medicines Raises $122 Million to Advance CAR-T Candidates Into Human Trials
The biotechnology company, formerly known as Myeloid Therapeutics, secured the funding from Newpath Partners, ARCH Venture Partners and Hatteras Venture Partners. CREATE Medicines, cofounded by Siddhartha Mukherjee, is developing CAR-T therapies using myeloid cells to target solid tumors and has expanded into autoimmune disease research.
rte.ieCREATE Medicines has raised $122 million to propel the company’s first CAR-T candidates through human trials, the biotech told STAT exclusively. The funding round included Newpath Partners, ARCH Venture Partners and Hatteras Venture Partners. CREATE Medicines is developing CAR-T therapies using a type of immune agent called myeloid cells.
Up until last year, CREATE Medicines was known as Myeloid Therapeutics. The startup was cofounded by noted writer and oncologist Siddhartha Mukherjee to develop better CAR-T therapies, ideally to better attack solid tumors. The company rebranded last fall.
It expanded into autoimmune disease research, following a path taken by many other oncology CAR-T companies. CREATE Medicines plans to advance its first CAR-T candidates through human trials with the new capital. Executives express confidence they will win the “foot race” in a competitive field, according to the STAT report published May 14, 2026.
The article was written by Allison DeAngelis. Stat reported that the $122 million funding arrives as the company operates with a new name and an expanded pipeline. A 3-D illustration of CAR-T cell therapy in breast cancer accompanied the report.
Stat reported the details of the funding and the company’s strategic shifts in an exclusive story available to STAT+ subscribers.
Key Facts
Story Timeline
3 events- 2025
CREATE Medicines known as Myeloid Therapeutics until last year
1 sourceStat - Fall 2025
CREATE Medicines rebranded and expanded into autoimmune disease research
1 sourceStat - May 14, 2026
CREATE Medicines announces $122 million funding round to STAT
1 sourceStat
Potential Impact
- 01
Funding enables first CAR-T candidates to enter human trials
- 02
Expansion into autoimmune indications broadens pipeline beyond oncology
- 03
Positions CREATE Medicines in competitive CAR-T field with new capital
Transparency Panel
Related Stories
France 24Zambia’s Kabwe Residents Sue Mining Company Over Lead Contamination
Children in Kabwe, Zambia, show blood lead levels above World Health Organization limits after decades of mining. An estimated 140,000 women and children have joined a class-action lawsuit against Anglo American South Africa Limited.
citizen.co.zaEbola Outbreak in Eastern DRC Kills at Least 240 Since Early May
The virus has spread from Ituri province into other eastern DRC regions and Uganda. Health workers report reduced international aid and limited local resources as they attempt to contain transmission.
manilatimes.netOutbreaks of hantavirus and Ebola prompt U.S. quarantine and travel measures
The U.S. government ordered quarantines after a hantavirus outbreak on a cruise ship and imposed new traveler restrictions during an Ebola outbreak in Africa. Federal agencies stated that response operations continue despite recent staffing reductions at health agencies.